FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog
December 11, 2017 at 13:13 PM EST
Dec 11 (Reuters) - The U.S. Food and Drug Administration said on Monday it approved Sanofi SA's Admelog as the first follow-on biologic version of Eli Lilly and Co's fast-acting insulin, Humalog.